WP
KYMR icon

Woodline Partners’s Kymera Therapeutics KYMR Stock Holding History

Woodline Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.4M Buy
500,868
+297,283
+146% +$25.5M 0.18% 146
2026
Q1 		$17M Hold
203,585
– – 0.06% 373
2025
Q4 		$15.8M Sell
203,585
-44,415
-18% -$3M 0.06% 358
2025
Q3 		$14M Sell
248,000
-250,111
-50% -$11.3M 0.07% 354
2025
Q2 		$21.7M Sell
498,111
-27,134
-5% -$934K 0.11% 264
2025
Q1 		$14.4M Sell
525,245
-12,183
-2% -$444K 0.09% 297
2024
Q4 		$21.6M Buy
537,428
+12,334
+2% +$557K 0.15% 199
2024
Q3 		$24.9M Buy
525,094
+7,297
+1% +$322K 0.21% 156
2024
Q2 		$15.5M Buy
517,797
+16,867
+3% +$584K 0.15% 199
2024
Q1 		$20.1M Buy
500,930
+400,179
+397% +$14.3M 0.19% 169
2023
Q4 		$2.57M Sell
100,751
-2,438
-2% -$43.6K 0.03% 366
2023
Q3 		$1.43M Sell
103,189
-5,592
-5% -$112K 0.02% 419
2023
Q2 		$2.5M Buy
108,781
+8,771
+9% +$251K 0.03% 402
2023
Q1 		$2.96M Buy
100,010
+10
+0% +$323 0.04% 373
2022
Q4 		$2.5M Hold
100,000
– – 0.03% 449
2022
Q3 		$2.18M Hold
100,000
– – 0.03% 446
2022
Q2 		$1.97M Buy
+100,000
New +$2.34M 0.03% 430
2021
Q4 		– Sell
-129,331
Closed -$7.6M – 750
2021
Q3 		$7.6M Buy
129,331
+91,572
+243% +$5.31M 0.12% 198
2021
Q2 		$1.83M Buy
+37,759
New +$1.64M 0.03% 374
2021
Q1 		– Sell
-169,687
Closed -$10.5M – 451
2020
Q4 		$10.5M Buy
169,687
+3,470
+2% +$169K 0.28% 112
2020
Q3 		$5.37M Buy
+166,217
New +$5.07M 0.18% 124

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Woodline Partners's KYMR Position: Q2 2026 in Review

Woodline Partners increased its Kymera Therapeutics (KYMR) stake by 146% in Q2 2026, buying an estimated $25.5M and bringing the position to 500,868 shares worth $57.4M. The position accounts for 0.18% of the portfolio, ranked #146.

Woodline Partners first reported a position in KYMR in Q3 2020 and has held it in 21 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Woodline Partners held 500,868 shares of Kymera Therapeutics worth $57.4M as of Q2 2026.
  • Woodline Partners bought 297,283 Kymera Therapeutics shares in Q2 2026, an estimated $25.5M.
  • Kymera Therapeutics made up 0.18% of Woodline Partners's portfolio in Q2 2026, its #146 holding.
  • Woodline Partners first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.